Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04908202 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT04908202 · ClinicalTrials.gov record · last posted 2026-04-23

A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs

StatusActive, Not Recruiting
PhasePhase 3
Started2021-07-13
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis who are naïve to biologic disease-modifying anti-rheumatic drugs. The long term extension period will provide additional long-term efficacy and safety information.

Amendment record 70 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 70 times since 2021-05-28; most recent amendment 2026-04-03. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-05-21
Status change Recruiting→Active, Not Recruitingv63
2021-07-30
Status change Not Yet Recruiting→Recruitingv1
Trial Details
NCT Number NCT04908202
Lead Sponsor Bristol-Myers Squibb
Conditions Psoriatic Arthritis
Enrollment 670 participants
Start Date 2021-07-13
Primary Completion 2024-09-05 (estimated)
Study Completion 2027-06-10 (estimated)
Updated on ClinicalTrials.gov 2026-04-23